Literature DB >> 25898798

The use of animal models in multiple myeloma.

H Libouban1.   

Abstract

In myeloma, the understanding of the tissular, cellular and molecular mechanisms of the interactions between tumor plasma cells and bone cells have progressed from in vitro and in vivo studies. However none of the known animal models of myeloma reproduce exactly the human form of the disease. There are currently three types of animal models: (1) injection of pristane oil in BALB/c mice leads to intraperitoneal plasmacytomas but without bone marrow colonization and osteolysis; (2) injection of malignant plasma cell lines in immunodeficient mice SCID or NOD/SCID; the use of the SCID-hu or SCID-rab model allows the use of fresh plasma cells obtained from MM patients; (3) injection of allogeneic malignant plasma cells (5T2MM, 5T33) in the C57BL/KalwRij mouse induces bone marrow proliferation and osteolytic lesions. These cells did not grow in vitro and can be propagated by injection of plasma cells isolated from bone marrow of a mouse at end stage of the disease into young recipient mice. The 5TGM1 is a subclone of 5T33MM cells and can grow in vitro. Among the different models, the 5TMM models and SCID-hu/SCID-rab models were extensively used to test pathophysiological hypotheses and to assess anti-osteoclastic, anti-osteoblastic or anti-tumor therapies in myeloma. In the present review, we report the different types of animal models of MM and describe their interests and limitations.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  5T2MM; 5T33MM; 5TGM1; BALB/c; C57BL/KalwRij; Modèle murin de myélome; Murine model of myeloma; Osteolysis; Ostéolyse; Pristane; SCID; SCID-hu; Xenograft; Xénogreffe

Mesh:

Substances:

Year:  2015        PMID: 25898798     DOI: 10.1016/j.morpho.2015.01.003

Source DB:  PubMed          Journal:  Morphologie        ISSN: 1286-0115


  3 in total

Review 1.  Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.

Authors:  Michaela R Reagan; Clifford J Rosen
Journal:  Nat Rev Rheumatol       Date:  2015-11-26       Impact factor: 20.543

2.  Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model.

Authors:  Maaike V J Braham; Monique C Minnema; Tineke Aarts; Zsolt Sebestyen; Trudy Straetemans; Anna Vyborova; Jurgen Kuball; F Cumhur Öner; Catherine Robin; Jacqueline Alblas
Journal:  Oncoimmunology       Date:  2018-02-22       Impact factor: 8.110

3.  Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance.

Authors:  Yanhua Yue; Yang Cao; Xunyuan Mao; Fei Wang; Peng Fan; Long Qian; Shuxin Guo; Feng Li; Yanting Guo; Tongbing Chen; Yan Lin; Weimin Dong; Yue Liu; Yuhui Huang; Weiying Gu
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.